Re-irradiation for locally recurrent refractory breast cancer

Tomas Merino; William T. Tran; Gregory J. Czarnota

doi:10.18632/oncotarget.6036

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Re-irradiation for locally recurrent refractory breast cancer

Tomas Merino, William T. Tran and Gregory J. Czarnota _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:35051-35062. https://doi.org/10.18632/oncotarget.6036

Metrics: PDF 2454 views | HTML 3112 views | ?

Abstract

Tomas Merino1,2,3, William T. Tran1 and Gregory J. Czarnota1,2

1 Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada

2 Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, Canada

3 Departamento de Hemato-Oncologia, Pontificia Universidad Catolica de Chile, Santiago, Chile

Correspondence to:

Gregory J. Czarnota, email:

Keywords: breast cancer, radiotherapy, re-irradiation, recurrent, refractory breast cancer

Received: May 25, 2015 Accepted: August 31, 2015 Published: October 08, 2015

Abstract

Purpose: To report an analysis of treatment outcomes of a cohort of patients re-irradiated for locally recurrent refractory breast cancer (LRRBC)

Patients and Methods: Between 2008 and 2013, 47 women (mean age = 60 years) were re-irradiated for LRRBC. Outcomes were measured using Kaplan-Meier log rank to compare curves and Cox regression for multivariate analysis. Outcomes included overall survival (OS), time to re-treatment, survival without systemic progression, and survival without local recurrence.

Results: Fifty-six instances of re-irradiation were completed and analyzed. The mean cumulative 2 Gy equivalent dose (EQD2) to the whole breast and tumour cavity (α/β = 3) was 99.8 Gy and 109.1 Gy, respectively. Most patients initially had significant symptoms before RT due to local recurrence. The median time to re-treatment and to systemic failure was 41 and 50 months, respectively. Median follow-up for OS was 17 months and OS was 0.73 (SE = 0.07) at 1 year and 0.67 (SE = 0.07) at 2 years. Local control was 0.62 (SE = 0.07) and 0.5 (0.08) at 1 and 2 years, respectively. Acute radiation dermatitis was G1-2, G3 and G4 in 45, 4 and 1 cases, respectively. One patient presented with necrosis. The most common long term toxicity was G3 fibrosis (n = 4) and telangiectatic changes (n = 3). Multivariable analysis indicated that skin involvement (Hazard Ratio = 6.6 (1.4-31), p = 0.016) and time to local recurrence <2yr (HR 3.1 (1.04-9.7) p = 0.042) predicted local recurrence.

Conclusion: High dose re-irradiation is feasible for locally RRBC. This approach can have a significant benefit in this very high-risk group.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6036

Publication Alerts

Post-Publication Promotion

Publication Discount

Clinical Research Papers:

Re-irradiation for locally recurrent refractory breast cancer

Abstract